Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)
Hong Kong · Delayed Price · Currency is HKD 191.20
-0.80 (-0.42%)
Sep 2, 2026, 10:14 AM HKT
HKG:2637 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 593.9 | 582.36 | 466.68 | 316.63 | 212.47 | |
Revenue Growth | - | 24.79% | 47.39% | 49.03% | - |
Cost of Revenue | 112.65 | 96.8 | 79.49 | 52.99 | 40.39 |
Gross Profit | 481.25 | 485.56 | 387.19 | 263.64 | 172.07 |
Selling, General & Admin | 220.38 | 219.79 | 186.64 | 107.3 | 56.9 |
Research & Development | 87.15 | 73.5 | 67.53 | 36.06 | 34.82 |
Operating Expenses | 303.78 | 293.3 | 254.17 | 143.36 | 91.72 |
Operating Income | 177.47 | 192.26 | 133.03 | 120.28 | 80.35 |
Interest Expense | -6.01 | -5.74 | -7.22 | -7.75 | -24.73 |
Interest & Investment Income | 15.02 | 8.93 | 5.64 | 7.09 | 6.39 |
Currency Exchange Gain (Loss) | -4.88 | -4.88 | - | - | - |
Other Non Operating Income (Expenses) | -9.98 | 6.1 | 16.41 | 13.23 | 11.92 |
EBT Excluding Unusual Items | 171.61 | 196.67 | 147.85 | 132.85 | 73.92 |
Gain (Loss) on Sale of Investments | -11.28 | 1.56 | 1.14 | - | -0.14 |
Gain (Loss) on Sale of Assets | -0.14 | -0.15 | - | -0.03 | -0.02 |
Pretax Income | 159.49 | 198.08 | 148.99 | 132.81 | 73.76 |
Income Tax Expense | 9.21 | 21.05 | 12.92 | 15.36 | 4.78 |
Net Income | 150.27 | 177.03 | 136.08 | 117.45 | 68.98 |
Net Income to Common | 150.27 | 177.03 | 136.08 | 117.45 | 68.98 |
Net Income Growth | - | 30.09% | 15.86% | 70.27% | - |
Shares Outstanding (Basic) | 75 | 70 | 67 | 67 | 64 |
Shares Outstanding (Diluted) | 75 | 70 | 67 | 67 | 64 |
Shares Change | - | 3.42% | - | 4.57% | - |
EPS (Basic) | 2.00 | 2.55 | 2.02 | 1.75 | 1.07 |
EPS (Diluted) | 2.00 | 2.55 | 2.02 | 1.75 | 1.07 |
EPS Growth | - | 25.79% | 15.86% | 62.83% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | - | 115.09 | -14.62 | 88.39 | 82.24 |
Free Cash Flow Per Share | - | 1.66 | -0.22 | 1.31 | 1.28 |
Gross Margin | 81.03% | 83.38% | 82.97% | 83.26% | 80.99% |
Operating Margin | 29.88% | 33.01% | 28.51% | 37.99% | 37.82% |
Profit Margin | 25.30% | 30.40% | 29.16% | 37.09% | 32.47% |
Free Cash Flow Margin | - | 19.76% | -3.13% | 27.92% | 38.71% |
EBITDA | 184.46 | 197.9 | 135.96 | 122.61 | 82.23 |
EBITDA Margin | 31.06% | 33.98% | 29.13% | 38.72% | 38.70% |
D&A For EBITDA | 6.99 | 5.64 | 2.93 | 2.33 | 1.88 |
EBIT | 177.47 | 192.26 | 133.03 | 120.28 | 80.35 |
EBIT Margin | 29.88% | 33.01% | 28.51% | 37.99% | 37.82% |
Effective Tax Rate | 5.78% | 10.63% | 8.67% | 11.56% | 6.48% |